TURALIO™

Pre-clinicalRecruiting

1 views this week 0 watching💤 Quiet

Interest: 33/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hepatotoxicity

Conditions

Hepatotoxicity, Tenosynovial Giant Cell Tumor

Trial Timeline

Jan 7, 2021 → Jun 1, 2036

NCT ID

NCT04635111

About TURALIO™

TURALIO™ is a pre-clinical stage product being developed by Daiichi Sankyo for Hepatotoxicity. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04635111. Target conditions include Hepatotoxicity, Tenosynovial Giant Cell Tumor.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04635111	Pre-clinical	Recruiting	Jan 7, 2021	Jun 1, 2036	Hepatotoxicity